Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
2.170
-0.100 (-4.41%)
Mar 31, 2025, 4:00 PM EDT - Market closed
CELZ Revenue
In the year 2024, Creative Medical Technology Holdings had annual revenue of $11.00K with 22.22% growth. Creative Medical Technology Holdings had revenue of $3.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$11.00K
Revenue Growth
+22.22%
P/S Ratio
360.81
Revenue / Employee
$2,750
Employees
4
Market Cap
3.79M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CELZ News
- 11 days ago - Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain - GlobeNewsWire
- 25 days ago - Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds - GlobeNewsWire
- 6 weeks ago - Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™ - GlobeNewsWire
- 6 weeks ago - Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program - GlobeNewsWire
- 7 weeks ago - Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development - GlobeNewsWire
- 2 months ago - Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain - GlobeNewsWire
- 4 months ago - Top 3 Real Estate Stocks That May Explode In Q4 - Benzinga
- 4 months ago - Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment - GlobeNewsWire